Back to Market返回行情

ACON Aclarion, Inc.

USHealthcare
$2.84-2.27%ClosedMarket Cap: $1.5M

As of 2026-07-10 16:00

Why ACON matters now

Aclarion, Inc. (ACON) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.84 with -2.27% on the session and $1.5M in market capitalization; recent performance reads 1-month -2.50% and YTD -32.17%.

The latest financial table shown here is Q1 2026, with revenue of $21.1K, net income of $-2.9M, and EPS of $-1.34. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -441.4%.

The latest indexable market news headline is "Aclarion Announces Texas Spine Care Center as New CLARITY Site" from MCAP MediaWire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Deitsch Stephen filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

0.34

P/S

21.37

EV/EBITDA

2.22

DCF Value

$20.54

FCF Yield

-441.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

-58.9%

Operating Margin

-10975.1%

Net Margin

-10336.1%

ROE

-54.4%

ROA

-39.0%

ROIC

-43.5%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$21.1K$-2.9M$-1.34
Q4 2025$18.5K$-1.9M$-2.21
FY 2025$75.7K$-7.2M$-13.61
Q3 2025$18.9K$-1.7M$-2.93

Analyst Ratings

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

Strong Buy: 0Buy: 1Hold: 0Sell: 0Strong Sell: 0
Ascendiant CapitalBuy
2026-05-29
Ascendiant CapitalBuy
2026-03-25
Ascendiant CapitalBuy
2025-11-20
Ascendiant CapitalBuy
2025-09-19

Trading Activity

Insider Trades

Deitsch Stephendirector
Sell2026-06-12
Neal David Kdirector
Sell2026-06-12
Thramann Jeffrey Johndirector, officer: Executive Chairman
Sell2026-06-12
Wesemann Williamdirector
Sell2026-06-12
Ness Brentdirector, officer: Chief Executive Officer
Sell2026-06-12

Company Info

Sector

Healthcare

Industry

Medical - Healthcare Information Services

Country

US

Exchange

Beta

1.22

Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.